

**FORM 51-102F3  
MATERIAL CHANGE REPORT**

**Item 1 Name and Address of Company**

HYTN Innovations Inc. (the “Company”)  
12 East 4th Avenue  
Vancouver, BC  
Canada V5T 1E8

**Item 2 Date of Material Change**

April 3, 2024

**Item 3 News Release**

The Company disseminated a news release announcing the material change described herein through the news dissemination service of Globe Newswire on April 3, 2024, and a copy was subsequently filed on SEDAR+.

**Item 4 Summary of Material Change**

The Company provides an update on its new strategic goals and plans for global commercialization.

**Item 5 Full Description of Material Change**

**5.1 Full Description of Material Change**

The Company provides an update on its new strategic goals and plans for global commercialization. This follows the recent achievement of Good Manufacturing Practices (GMP) certification for the Company’s Kelowna production facility by Australia's Therapeutic Goods Administration (TGA) under the Pharmaceutical Inspection Co-operation Scheme (PIC/S) standard.

The Company is announcing two strategic commercial initiatives underscoring the Company’s commitment to leading the GMP-certified cannabis products industry. Firstly, the Company will focus on transforming Canadian-grown cannabis into final medical products that meet GMP standards and are ready for export to an international customer base. The Company expects to commercialize both business to business and wholesale opportunities under this initiative. Additionally, the Company aims to unlock global markets for established cannabis brands by leveraging the Company's regulatory compliance, supply chain capabilities and Quality Management System. This initiative will allow for the rapid penetration of existing brands into highly regulated markets.

The Company's strategic advancement is well-timed with the opening of Germany's medical cannabis market, projected to be valued at more than \$2 Billion. This development complements the growing demand in other regions where medical cannabis is legal, including Australia—a country where the Company has already established a successful export footprint. The Company's GMP certification meets EU-GMP criteria and reflects strict adherence to those standards through rigorous quality system audits. Additionally, the Company’s collaboration with Promethean Biopharma in Australia, who sponsored the TGA audit, further reinforces the Company's commitment to quality and compliance with stringent GMP requirements.

**5.2 Disclosure for Restructuring Transactions**

Not applicable.

**Item 6 Reliance on Subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7 Omitted Information**

Not applicable.

**Item 8 Executive Officer**

For further information, please contact Elliot McKerr, Chief Executive Officer of 866-590-9289 or via email to [investments@hytn.life](mailto:investments@hytn.life).

**Item 9 Date of Report**

April 4, 2024